Amprologix
@amprologix.bsky.social
Amprologix, launched in 2018 in collaboration with University of Plymouth, has pioneered a drug discovery programme focused on identifying the next generation of antibiotics.
www.amprologix.com
https://www.linkedin.com/company/amprologix-limited/
www.amprologix.com
https://www.linkedin.com/company/amprologix-limited/
We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide.
Amprologix Selected for MassChallenge Switzerland & UK 2025 Accelerator - Amprologix
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme ...
www.amprologix.com
July 16, 2025 at 4:58 PM
We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide.
Epidermicin NI01, has been featured in EMJ Reviews following a presentation by CSO @matupton.bsky.social at @escmid.bsky.social Global 2025.
The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.
The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.
Epidermicin NI01, a First-in-Class Peptide Antibiotic Candidate, Has Potent Efficacy in a Robust MRSA Wound Infection Model and Low Allergic Reaction Liabilities
Over 10% of antibiotic prescriptions are for skin infections.1,2 New therapeutic approaches are required, and new modalities may be...
www.emjreviews.com
June 16, 2025 at 10:59 AM
Epidermicin NI01, has been featured in EMJ Reviews following a presentation by CSO @matupton.bsky.social at @escmid.bsky.social Global 2025.
The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.
The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.
@matupton.bsky.social, CSO, recently presented results from ongoing research at ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - in Vienna
www.plymouth.ac.uk/news/studies...
www.plymouth.ac.uk/news/studies...
Studies shows new class of antibiotic is effective in tackling MRSA
University of Plymouth news: The latest results of ongoing research by the University, and spinout company Amprologix, will be presented to leading...
www.plymouth.ac.uk
May 21, 2025 at 8:45 AM
@matupton.bsky.social, CSO, recently presented results from ongoing research at ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - in Vienna
www.plymouth.ac.uk/news/studies...
www.plymouth.ac.uk/news/studies...